Market Survey

Early Sepsis Detection Using Earlobe Monitoring for Better bed Patient Care

A.D.U.Dewmini-D ENG 23 0160 BM

Key findings

According to the World Health Organization (WHO), sepsis accounts for approximately 20% of globa deaths, with 11 million deaths out of 48.9 million cases worldwide. It remains a leading cause of hospital mortality, particularly in low- and middle-income countries

Market Awareness

Current Sepsis Detection Devices

DEVICE TYPE	Estimated Cost per Unit
Electronic-Nose (E-Nose) Devices	590,780 – 1,476,950 LKR($2,000 – $5,000)
Machine Learning-Based Monitoring Systems	14,769,500 – 59,078,000 LKR($50,000 – $200,000)
Biomarker-Based Diagnostic Kits	5,908 – 59,078 LKR per test($20 – $200 per test)
Wearable Biosensors	147,695 – 738,475 LKR($500 – $2,500)

Comparative Analysis

Technology

Electronic-nose devices detect sepsis using volatile organic compounds (VOCs) in breath or bodily fluids, while biomarker-based kits analyze blood samples for sepsis indicators such as procalcitonin (PCT) and C-reactive protein (CRP). On the other hand, machine learning-based systems use electronic health records (EHR) and real-time patient data to predict septic shock, whereas wearable biosensors continuously monitor vital signs like heart rate, oxygen saturation, and temperature

Electronic-nose devices analyze chemical signatures in breath, while biomarker-based kits detect specific proteins associated with sepsis. In contrast, machine learning models assess a combination of clinical data, including past patient records and symptoms, whereas wearable biosensors track real-time physiological signs to detect anomalies.

Speed

Biomarker-based diagnostic kits provide results within minutes to a few hours, while conventional blood cultures take 24-48 hours. Electronic-nose devices work faster, potentially detecting sepsis within seconds to minutes. However, machine learning models require data collection over time to predict trends, while wearable biosensors continuously track vital signs but may need hours to days to indicate sepsis onset.

Accuracy

Machine learning models achieved up to 88.1% specificity and 83.9% sensitivity, while biomarker kits provide high specificity but may fail if infection markers are not elevated at the time of testing. Electronic-nose devices show promise but require further validation, while wearable biosensors are highly sensitive but may generate false alarms if not properly calibrated

Target group →

Bedridden Patients in Home Care

- Elderly Patients- Elders with weakened immune systems who are more prone to infections leading to sepsis.
- Post-Surgical Patients- Individuals recovering from surgery who have a higher risk of infections.
- Chronically Ill Patients-Those with conditions like diabetes, kidney disease, or cancer, which can increase sepsis risk.

Regulations

Medical Device Classification
sepsis detection device I design is likely a Class II medical device since it is a non-invasive continuous monitoring device under FDA (U.S.) and Class IIa or IIb under EU MDR, requiring moderate regulatory controls. Similar classifications apply in UK (MHRA) and India (CDSCO) based on risk assessment.

Regulatory Approval Process
To enter global markets, device must meet specific regulatory approval processes. In the U.S., a 510(k) premarket notification is required if a similar product exists; otherwise, a De Novo classification applies for new innovations. In Europe, CE marking under ISO 13485 ensures compliance with safety and quality standards.

Safety and Compliance Standards
Ensuring patient safety and data protection is critical. Compliance with ISO 13485 (medical device quality standards) and IEC 60601-1 (electrical safety) ensures device reliability. Additionally, if the device transmits patient data, it must adhere to HIPAA (U.S.) and GDPR (EU) regulations for privacy and cybersecurity.

Clinical Trials and Testing
Before market entry, device must undergo preclinical testing to validate its accuracy, sensitivity, and specificity in detecting sepsis indicators. In high-risk applications, clinical trials may be necessary to prove efficacy and safety. The approval process may involve hospital trials, ensuring real-world effectiveness before regulatory clearance.

Market-Specific Requirements
Clear labeling and instructions are necessary for safe operation in hospitals and home care.

Availability of patient rights

Existing Patents in Sepsis Detection

- Machine Learning & AI-Based Sepsis Detection – Patents related to predictive algorithms using patient vital signs and lab results to detect sepsis earlier.
- Biomarker-Based Sepsis Kits – Patents on test kits that detect interleukin-6 (IL-6), procalcitonin (PCT), and C-reactive protein (CRP) to diagnose sepsis.
- Wearable Sepsis Detection Devices – Patents for continuous monitoring biosensors integrated into smart patches and portable medical devices.

Patent Gaps (Opportunities for New Patents)

- Home-Based Sepsis Monitoring – Most patents focus on hospital use, creating a market gap for a home-use wearable device.
- Real-Time AI Integration – AI-driven early warning devices for continuous monitoring remain underexplored.
- Non-Invasive Sepsis Detection – Innovations in breath analysis or skin-based diagnostics could be patentable.

Freedom to Operate (FTO) Analysis

The availability of patent rights for early sepsis detection devices shows a competitive landscape with multiple existing patents covering biomarker-based detection kits, AI-driven predictive models, and wearable biosensors. Despite this, there are opportunities for innovation, particularly in home-based sepsis monitoring, real-time AI integration, and non-invasive diagnostic methods. Conducting a Freedom to Operate (FTO) analysis is crucial before launching a new device to avoid infringement on existing patents. This involves searching databases like USPTO, WIPO, and PATENTSCOPE, identifying any active patents restricting commercialization, and exploring patent licensing or unique technology differentiation. Securing a patent can provide market exclusivity, increase investor confidence, and strengthen regulatory approval. Your device could stand out by focusing on continuous home monitoring, AI-driven early warnings, and wearable non-invasive detection, which remain underdeveloped in the market.